Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab With or Without Tremelimumab in Advanced Solid Malignancies With or Without Standard Chemotherapy
NCT02537418Phase 1Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Oct 2015
- Primary completion
- Jul 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in solid malignancy, sponsored by Canadian Cancer Trials Group. Primary endpoint: Recommended Phase II Dose at 24 months. Started Oct 2015; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
solid malignancy
Beyond the preview
Go deeper on NCT02537418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537418.